This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: April 16th, 2012 - April 16th, 2013
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.
The activity was developed for physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma (MM).
Upon completion of this activity, the participant will be able to:
Use diagnostic and staging criteria to distinguish active multiple myeloma (MM) from smoldering MM and monoclonal gammopathy of undetermined significance
Determine appropriate treatment for newly-diagnosed MM based on patient- and disease-related characteristics and the riskbenefit profile of available agents and combinations
Apply evidence-based strategies to prevent and/or manage common comorbidities in patients with MM
Agenda - 1.25 hours
- Articles/Commentaries: 60 minutes
- Evaluation/Post-Test: 15 minutes
Physician Credit Designation
The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and the Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.
Registered Pharmacy Designation
Medical Learning Institute, Inc. (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-12- 012-H01-P.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship( s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
*Content will include non-FDA-approved uses.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Name of Planner
|Dana Delibovi||COEXM||Nothing to disclose|
|William J. Wong, MD||MLI||Nothing to disclose|
|Patricia A. Ensor, RPh, MBA||MLI||Nothing to disclose|
|Judith A. Bonomi, RN, MS, MSN, OCN||MLI||has disclosed that her spouse is investigator on a study for Agenix and Lilly; on the data monitoring committee for Infinity; and on the data monitoring committee and PI on a study for Pfizer.|
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.